Stevens‐Johnson syndrome: Pathogenesis, diagnosis, and management

References

• Chung W. H., Hung S. I., Hong H. S., Hsih M. S., Yang L. C., Ho H. C., et al. Medical genetics: a marker for Stevens‐Johnson syndrome. Nature 2004; 428: 486
   PubMed Web of Science ®Google Scholar
• Ruiz‐Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13: 623–35
   Google Scholar
• Hussain W., Craven N. M. Toxic epidermal necrolysis and Stevens‐Johnson syndrome. Clin Med 2005; 5: 555–8
   Google Scholar
• Kumar G., Fadel H. J., Beckman T. J. 36‐year‐old man with productive cough and diffuse rash. Mayo Clin Proc 2006; 81: 945–8
   Google Scholar
• Leaute‐Labreze C., Lamireau T., Chawki D., Maleville J., Taieb A. Diagnosis, classification, and management of erythema multiforme and Stevens‐Johnson syndrome. Arch Dis Child 2000; 83: 347–52
   Google Scholar
• Paquet P., Pierard G. E. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997; 19: 127–32
   PubMed Web of Science ®Google Scholar
• Kasper M. Stevens‐Johnson syndrome. Clin J Oncol Nurs 2001; 5: 25–6
   Google Scholar
• Wolf R., Davidovici B., Matz H., Mahlab K., Orion E., Sthoeger Z. M. Drug Rash with eosinophilia and systemic symptoms versus Stevens‐Johnson Syndrome—a case that indicates a stumbling block in the current classification. Int Arch Allergy Immunol 2006; 141: 308–10
   PubMed Web of Science ®Google Scholar
• Hansen R. C. Blindness, anonychia, and oral mucosal scarring as sequelae of the Stevens‐Johnson syndrome. Pediatr Dermatol 1984; 1: 298–300
   Google Scholar
• Powell N., Munro J. M., Rowbotham D. Colonic involvement in Stevens‐Johnson syndrome. Postgrad Med J 2006; 82: e10
   Google Scholar
• Hart R., Minto C., Creighton S. Vaginal adhesions caused by Stevens‐Johnson syndrome. J Pediatr Adolesc Gynecol 2002; 15: 151–2
   PubMedGoogle Scholar
• Ayangco L., Rogers R. S 3rd. Oral manifestations of erythema multiforme. Dermatol Clin 2003; 21: 195–205
   Google Scholar
• Manders S. M. Serious and life‐threatening drug eruptions. Am Fam Physician 1995; 51: 1865–72
   PubMedGoogle Scholar
• Vanfleteren I., Van Gysel D., De Brandt C. Stevens‐Johnson syndrome: a diagnostic challenge in the absence of skin lesions. Pediatr Dermatol 2003; 20: 52–6
   Google Scholar
• Lowndes S., Darby A., Mead G., Lister A. Stevens‐Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948–50
   PubMed Web of Science ®Google Scholar
• Singla R., Brodell R. T. Erythema multiforme due to herpes simplex virus. Recurring target lesions are clue to diagnosis. Postgrad med 1999; 106: 151–4
   Google Scholar
• Dart J. PL3 Stevens Johnson syndrome and mucous membrane pemphigoid: ocular manifestations and their management. Oral Dis 2006; 12 Suppl 1: 1
   Google Scholar
• Di Pascuale M. A., Espana E. M., Liu D. T., Kawakita T., Li W., Gao Y. Y., et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens‐Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 2005; 112: 904–12
   PubMed Web of Science ®Google Scholar
• Wall V., Yen M. T., Yang M. C., Huang A. J., Pflugfelder S. C. Management of the late ocular sequelae of Stevens‐Johnson syndrome. Ocul Surf 2003; 1: 192–201
   PubMedGoogle Scholar
• Graham‐Brown R. A., Cochrane G. W., Swinhoe J. R., Sarkany I., Epsztejn L. J. Vaginal stenosis due to bullous erythema multiforme (Stevens‐Johnson syndrome). Case report. Br J Obstet Gynaecol 1981; 88: 1156–7
   PubMedGoogle Scholar
• Wilson E. E., Malinak L. R. Vulvovaginal sequelae of Stevens‐Johnson syndrome and their management. Obstet Gynecol 1988; 71: 478–80
   Web of Science ®Google Scholar
• Murphy M. I., Brant W. E. Hematocolpos caused by genital bullous lesions in a patient with Stevens‐Johnson syndrome. J Clin Ultrasound 1998; 26: 52–4
   PubMedGoogle Scholar
• Noel J. C., Buxant F., Fayt I., Bebusschere G., Parent D. Vulval adenosis associated with toxic epidermal necrolysis. Br J Dermatol 2005; 153: 457–8
   Google Scholar
• Tan Y. M., Goh K. L. Esophageal stricture as a late complication of Stevens‐Johnson syndrome. Gastrointest Endosc 1999; 50: 566–8
   Google Scholar
• Rottermann E. M., Julia M. V., Rovira J., Pari F. J., Morales L. Esophageal stenosis following Stevens‐Johnson syndrome. Treatment with balloon dilation. Clin Pediatr (Phila) 1990; 29: 336–8
   Google Scholar
• Clayton N. A., Kennedy P. J. Management of Dysphagia in Toxic Epidermal Necrolysis (TEN) and Stevens‐Johnson Syndrome (SJS). Dysphagia 2007; 22: 187–92
   PubMed Web of Science ®Google Scholar
• Zweiban B., Cohen H., Chandrasoma P. Gastrointestinal involvement complicating Stevens‐Johnson syndrome. Gastroenterology 1986; 91: 469–74
   Google Scholar
• Kamada N., Kinoshita K., Togawa Y., Kobayashi T., Matsubara H., Kohno M., et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti‐Ro/SS‐A and a review of the published work. J Dermatol 2006; 33: 616–22
   PubMed Web of Science ®Google Scholar
• Martin L., Hazouard E., Michalak‐Provost S., Maurage C., Machet L. [Fatal toxic respiratory epitheliolysis. Subacute tracheo‐bronchial desquamation in Stevens‐Johnson syndrome]. Rev Pneumol Clin 2001; 57: 297–301
   Google Scholar
• Shah A. P., Xu H., Sime P. J., Trawick D. R. Severe airflow obstruction and eosinophilic lung disease after Stevens‐Johnson syndrome. Eur Respir J 2006; 28: 1276–9
   PubMedGoogle Scholar
• Peters M. E., Gourley G., Mann F. A. Esophageal stricture and web secondary to Stevens‐Johnson syndrome. Pediatr Radiol 1983; 13: 290–1
   Google Scholar
• Roujeau J. C., Stern R. S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272–85
   PubMed Web of Science ®Google Scholar
• Rzany B., Mockenhaupt M., Baur S., Schroder W., Stocker U., Mueller J., et al. Epidemiology of erythema exsudativum multiforme majus, Stevens‐Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population‐based registry. J Clin Epidemiol 1996; 49: 769–73
   PubMed Web of Science ®Google Scholar
• Chan H. L., Stern R. S., Arndt K. A., Langlois J., Jick S. S., Jick H., et al. The incidence of erythema multiforme, Stevens‐Johnson syndrome, and toxic epidermal necrolysis. A population‐based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43–7
   PubMed Web of Science ®Google Scholar
• Parrillo SJ, Parrillo CV. Stevens‐Johnson Syndrome. Emedicine website. Available at: http://www.emedicine.com/emerg/topic555.htm (accessed December 17, 2006)
   Google Scholar
• Shilad A., Predanic M., Perni S. C., Houlihan C., Principe D. Human immunodeficiency virus, pregnancy, and Stevens‐Johnson syndrome. Obstet Gynecol 2005; 105: 1254–6
   PubMed Web of Science ®Google Scholar
• Coopman S. A., Johnson R. A., Platt R., Stern R. S. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328: 1670–4
   PubMed Web of Science ®Google Scholar
• Gonzalez‐Delgado P., Blanes M., Soriano V., Montoro D., Loeda C., Niveiro E. Erythema multiforme to amoxicillin with concurrent infection by Epstein‐Barr virus. Allergol Immunopathol (Madr) 2006; 34: 76–8
   PubMedGoogle Scholar
• Ghislain P. D., Roujeau J. C. Treatment of severe drug reactions: Stevens‐Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8: 5
   PubMedGoogle Scholar
• Sanwo M., Nwadiuko R., Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. J Allergy Clin Immunol 1996; 98: 1112–5
   PubMedGoogle Scholar
• Samimi S. S., Siegfried E. Stevens‐Johnson syndrome developing in a girl with systemic lupus erythematosus on high‐dose corticosteroid therapy. Pediatr Dermatol 2002; 19: 52–5
   PubMed Web of Science ®Google Scholar
• Matsushita K., Ozaki A., Inoue H., Kaieda T., Akimoto M., Satomura A., et al. Stevens‐Johnson syndrome induced by mizoribine in a patient with systemic lupus erythematosus. Mod Rheumatol 2006; 16: 113–6
   PubMedGoogle Scholar
• Lonjou C., Thomas L., Borot N., Ledger N., de Toma C., LeLouet H., et al. A marker for Stevens‐Johnson syndrome …: ethnicity matters. Pharmacogenomics J 2006; 6: 265–8
   PubMed Web of Science ®Google Scholar
• Hung S. I., Chung W. H., Jee S. H., Chen W. C., Chang Y. T., Lee W. R., et al. Genetic susceptibility to carbamazepine‐induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297–306
   PubMed Web of Science ®Google Scholar
• Alfirevic A., Jorgensen A. L., Williamson P. R., Chadwick D. W., Park B. K., Pirmohamed M. HLA‐B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7: 813–8
   PubMed Web of Science ®Google Scholar
• Hung S. I., Chung W. H., Liou L. B., Chu C. C., Lin M., Huang H. P., et al. HLA‐B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134–9
   PubMed Web of Science ®Google Scholar
• Power W. J., Saidman S. L., Zhang D. S., Vamvakas E. C., Merayo‐Lloves J. M., Kaufman A. H., et al. HLA typing in patients with ocular manifestations of Stevens‐Johnson syndrome. Ophthalmology 1996; 103: 1406–9
   PubMedGoogle Scholar
• Bachot N., Roujeau J. C. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003; 4: 561–72
   PubMed Web of Science ®Google Scholar
• French L. E. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006; 55: 9–16
   PubMedGoogle Scholar
• DiSesa V. J., Kirkman R. L., Tilney N. L., Mudge G. H., Collins J. J Jr., Cohn L. H. Management of general surgical complications following cardiac transplantation. Arch Surg 1989; 124: 539–41
   Google Scholar
• Ostlere L. S., Harris D., Burroughs A. K., Rolles K. Toxic epidermal necrolysis after hepatic transplantation. Arch Dermatol 1992; 128: 1550–1
   Google Scholar
• Revuz J. E., Roujeau J. C. Advances in toxic epidermal necrolysis. Semin Cutan Med Surg 1996; 15: 258–66
   PubMedGoogle Scholar
• Mockenhaupt M., Norgauer J. Cutaneous Adverse Drug Reactions. Stevens‐Johnson syndrome and Toxic Epidermal Necrolysis. Allergy Clin Immunol Int 2002; 14: 143–50
   Google Scholar
• Schulz J. T., Sheridan R. L. Severe desquamating disorder after liver transplant: toxic epidermal necrolysis or graft versus host disease?. J Burns Wounds 2006; 5: e1
   PubMedGoogle Scholar
• Correia O., Delgado L., Barbosa I. L., Domingues J. C., Azevedo R., Vaz C. P., et al. CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft‐versus‐host disease: further similarities with toxic epidermal necrolysis. Dermatology 2001; 203: 212–6
   PubMedGoogle Scholar
• Asagoe K., Takahashi K., Yoshino T., Kondo E., Tanaka R., Arata J., et al. Numerical, morphological and phenotypic changes in Langerhans cells in the course of murine graft‐versus‐host disease. Br J Dermatol 2001; 145: 918–27
   PubMed Web of Science ®Google Scholar
• Bennet L., Halling A., Berglund J. Increased incidence of Lyme borreliosis in southern Sweden following mild winters and during warm, humid summers. Eur J Clin Microbiol Infect Dis 2006; 25: 426–32
   PubMed Web of Science ®Google Scholar
• Hubalek Z. North Atlantic weather oscillation and human infectious diseases in the Czech Republic, 1951–2003. Eur J Epidemiol 2005; 20: 263–70
   Web of Science ®Google Scholar
• Hilas O., Charneski L. Lamotrigine‐induced Stevens‐Johnson syndrome. Am J Health Syst Pharm 2007; 64: 273–275
   Web of Science ®Google Scholar
• Caproni M., Torchia D., Schincaglia E., Volpi W., Frezzolini A., Schena D., et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens‐Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006; 154: 319–24
   PubMedGoogle Scholar
• Hockett K. C. Stevens‐Johnson syndrome and toxic epidermal necrolysis: oncologic considerations. Clin J Oncol Nurs 2004; 8: 27–30; 55
   Google Scholar
• Severino G., Chillotti C., De Lisa R., Del Zompo M., Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 2005; 39: 162–4
   PubMed Web of Science ®Google Scholar
• Famularo G., De Simone C., Minisola G. Stevens‐Johnson syndrome associated with single high dose of lamotrigine in a patient taking valproate. Dermatol Online J 2005; 11: 25
   Google Scholar
• Vincenzi B., Santini D., Grilli C., La Cesa A., Dianzani C., Tonini G. Complications of therapy in cancer patients: Case 3. Toxic epidermal necrolysis induced by oral phenobarbital and whole‐brain radiotherapy in a breast cancer patient. J Clin Oncol 2004; 22: 4649–51
   PubMed Web of Science ®Google Scholar
• Ridgway H. B., Miech D. J. Erythema multiforme (Stevens‐Johnson syndrome) following deep radiation therapy. Cutis 1993; 51: 463–4
   Google Scholar
• Chopra A., Drage L. A., Hanson E. M., Touchet N. L. Stevens‐Johnson syndrome after immunization with smallpox, anthrax, and tetanus vaccines. Mayo Clin Proc 2004; 79: 1193–6
   Google Scholar
• Layton D., Marshall V., Boshier A., Friedmann P., Shakir S. A. Serious skin reactions and selective COX‐2 inhibitors: a case series from prescription‐event monitoring in England. Drug Saf 2006; 29: 687–96
   PubMed Web of Science ®Google Scholar
• Hofbauer G. F., Burg G., Nestle F. O. Cocaine‐related Stevens‐Johnson syndrome. Dermatology 2000; 201: 258–60
   Google Scholar
• Ventura M. T., Viola M., Calogiuri G., Gaeta F., Pesole O., Romano A. Hypersensitivity reactions to complementary and alternative medicine products. Curr Pharm Des 2006; 12: 3393–9
   PubMedGoogle Scholar
• Bastuji‐Garin S., Rzany B., Stern R. S., Shear N. H., Naldi L., Roujeau J. C. Clinical classification of cases of toxic epidermal necrolysis, Stevens‐Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92–6
   PubMed Web of Science ®Google Scholar
• Levy M., Shear N. H. Mycoplasma pneumoniae infections and Stevens Johnson syndrome: report of eight cases and review of the literature. Clin Pediatr 1991; 30: 42–9
   Google Scholar
• Ravin K. A., Rappaport L. D., Zuckerbraun N. S., Wadowsky R. M., Wald E. R., Michaels M. M. Mycoplasma pneumoniae and atypical Stevens‐Johnson syndrome: a case series. Pediatrics 2007; 119: e1002–5
   Google Scholar
• Detjen P. F., Patterson R., Noskin G. A., Phair J. P., Loyd S. O. Herpes simplex virus associated with recurrent Stevens‐Johnson syndrome. A management strategy. Arch Intern Med 1992; 152: 1513–6
   Google Scholar
• Ng P. P., Sun Y. J., Tan H. H., Tan S. H. Detection of herpes simplex virus genomic DNA in various subsets of Erythema multiforme by polymerase chain reaction. Dermatology 2003; 207: 349–53
   PubMedGoogle Scholar
• Hanno R., Bean S. F. Hodgkin's disease with specific bullous lesions. Am J Dermatopathol 1980; 2: 363–6
   Google Scholar
• Margolis R. J., Bhan A., Mihm M. C Jr., Bernhardt M. Erythema multiforme in a patient with T cell chronic lymphocytic leukemia. J Am Acad Dermatol 1986; 14: 618–27
   Google Scholar
• Klein PA. Stevens‐Johnson Syndrome. Emedicine website. Available at: http://www.emedicine.com/derm/topic405.htm (accessed August 30, 2007)
   Google Scholar
• Roychowdhury S., Svensson C. K. Mechanisms of drug‐induced delayed‐type hypersensitivity reactions in the skin. AAPS J 2005; 7: E834–46
   PubMed Web of Science ®Google Scholar
• Roujeau J. C. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123–9
   PubMed Web of Science ®Google Scholar
• Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233–43
   PubMed Web of Science ®Google Scholar
• Iwai K., Miyawaki T., Takizawa T., Konno A., Ohta K., Yachie A., et al. Differential expression of bcl‐2 and susceptibility to anti‐Fas‐mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994; 84: 1201–8
   PubMed Web of Science ®Google Scholar
• Khalili B., Bahna S. L. Pathogenesis and recent therapeutic trends in Stevens‐Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006; 97: 272–80
   PubMed Web of Science ®Google Scholar
• French L. E., Trent J. T., Kerdel F. A. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens‐Johnson syndrome: our current understanding. Int Immunopharmacol 2006; 6: 543–9
   PubMed Web of Science ®Google Scholar
• Inachi S., Mizutani H., Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens‐Johnson syndrome. Contribution of perforin‐positive cell infiltration. Arch Dermatol 1997; 133: 845–9
   Google Scholar
• Greenberger P. A. Drug allergy. J Allergy Clin Immunol 2006; 117: S464–70
   PubMed Web of Science ®Google Scholar
• Nakajima T., Yamanoshita O., Kamijima M., Kishi R., Ichihara G. Generalized skin reactions in relation to trichloroethylene exposure: a review from the viewpoint of drug‐metabolizing enzymes. J Occup Health 2003; 45: 8–14
   PubMed Web of Science ®Google Scholar
• Liechty C. A., Solberg P., Mwima G., Were W., Weidle P. J., Mermin J. Nevirapine‐induced Stevens‐Johnson syndrome in a mother and son. AIDS 2005; 19: 993–4
   Google Scholar
• Pirmohamed M. Genetic factors in the predisposition to drug‐induced hypersensitivity reactions. AAPS J 2006; 8: E20–6
   PubMed Web of Science ®Google Scholar
• Evans D. A. Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet 1984; 21: 243–53
   PubMed Web of Science ®Google Scholar
• Nassif A., Bensussan A., Dorothee G., Mami‐Chouaib F., Bachot N., Bagot M., et al. Drug specific cytotoxic T‐cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118: 728–33
   PubMed Web of Science ®Google Scholar
• Guegan S., Bastuji‐Garin S., Poszepczynska‐Guigne E., Roujeau J. C., Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272–6
   PubMed Web of Science ®Google Scholar
• Bastuji‐Garin S., Fouchard N., Bertocchi M., Roujeau J. C., Revuz J., Wolkenstein P. SCORTEN: a severity‐of‐illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149–53
   PubMed Web of Science ®Google Scholar
• Garcia‐Doval I., LeCleach L., Bocquet H., Otero X. L., Roujeau J. C. Toxic epidermal necrolysis and Stevens‐Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol 2000; 136: 323–7
   PubMed Web of Science ®Google Scholar
• Becker D. S. Toxic epidermal necrolysis. Lancet 1998; 351: 1417–20
   Web of Science ®Google Scholar
• Prendiville J. S., Hebert A. A., Greenwald M. J., Esterly M. B. Management of Stevens‐Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989; 115: 881–7
   PubMed Web of Science ®Google Scholar
• Peng Y. Z., Yuan Z. Q., Xiao G. X. Effects of early enteral feeding on the prevention of enterogenic infection in severely burned patients. Burns 2001; 27: 145–9
   Google Scholar
• Kelemen J. J 3rd., Cioffi W. G., McManus W. F. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180: 273–8
   PubMed Web of Science ®Google Scholar
• Murphy J. T., Purdue G. F., Hunt J. L. Toxic epidermal necrolysis. J Burn Care Rehabil 1997; 18: 417–20
   Google Scholar
• McGee T., Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998; 102: 1018–22
   PubMed Web of Science ®Google Scholar
• Paquet P., Jacob E., Quatresooz P., Jacquemin D., Pierard G. E. Delayed reepithelialization and scarring deregulation following drug‐induced toxic epidermal necrolysis. Burns 2007; 33: 100–4
   Google Scholar
• Sheridan R. L., Weber J. M., Schulz J. T., Ryan C. M., Low H. M., Tompkins R. G. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999; 20: 497–500
   PubMedGoogle Scholar
• Stoschus B., Allescher H. D. Drug‐induced dysphagia. . Dysphagia 1993; 8: 154–159
   PubMedGoogle Scholar
• Hallgren J., Tengvall‐Linder M., Persson M., Wahlgren C. F. Stevens‐Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol 2003; 49: S267–9
   PubMed Web of Science ®Google Scholar
• Yusin J. S., Crawford W. W., Klaustermeyer W. B. Facial edema, oral ulcers, and a cutaneous eruption following a dental procedure utilizing diflunisal and mepivacaine. Ann Allergy Asthma Immunol 1999; 83: 353–5
   Google Scholar
• Hynes A. Y., Kafkala C., Daoud Y. J., Foster C. S. Controversy in the use of high‐dose systemic steroids in the acute care of patients with Stevens‐Johnson syndrome. Int Ophthalmol Clin 2005; 45: 25–48
   Google Scholar
• Patterson R., Grammer L. C., Greenberger P. A., Lawrence I. D., Zeiss C. R., Detjen P. F., et al. Stevens‐Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc 1992; 13: 89–95
   PubMedGoogle Scholar
• Tripathi A., Ditto A. M., Grammer L. C., Greenberger P. A., McGrath K. G., Zeiss C. R., et al. Corticosteroid therapy in an additional 13 cases of Stevens‐Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000; 21: 101–5
   PubMed Web of Science ®Google Scholar
• Roujeau J. C. Treatment of severe drug eruptions. J Dermatol 1999; 26: 718–22
   PubMedGoogle Scholar
• Halebian P. H., Corder V. J., Madden M. R., Finklestein J. L., Shires G. T. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503–12
   PubMed Web of Science ®Google Scholar
• Engelhardt S. L., Schurr M. J., Helgerson R. B. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997; 18: 520–4
   Google Scholar
• Metry D. W., Jung P., Levy M. L. Use of intravenous immunoglobulin in children with Stevens‐Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003; 112: 1430–6
   PubMed Web of Science ®Google Scholar
• Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–3
   PubMed Web of Science ®Google Scholar
• Letko E., Papaliodis D. N., Papaliodis G. N., Daoud Y. J., Ahmed A. R., Foster C. S. Stevens‐Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94: 419–36
   PubMed Web of Science ®Google Scholar
• Yeung C. K., Lam L. K., Chan H. H. The timing of intravenous immunoglobulin therapy in Stevens‐Johnson syndrome and toxic epidermal necrolysis. Clin ExpDermatol 2005; 30: 600–2
   Google Scholar
• Prins C., Vittorio C., Padilla R. S., Hunziker T., Itin P., Forster J., et al. Effect of high‐dose intravenous immunoglobulin therapy in Stevens‐Johnson syndrome: a retrospective, multicenter study. Dermatology 2003; 207: 96–9
   PubMed Web of Science ®Google Scholar
• Daoud Y. J., Amin K. G. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol 2006; 6: 600–6
   PubMed Web of Science ®Google Scholar
• Tay Y. K., Huff J. C., Weston W. L. Mycoplasma pneumoniae infection is associated with Stevens‐Johnson syndrome, not erythema multiforme. J Am Acad Dermatol 1996; 35: 757–60
   Google Scholar
• Pitche P., Padonou C. S., Kombate K., Mouzou T., Tchangai‐Walla K. Stevens‐Johnson syndrome and toxic epidermal necrolysis in Lome (Togo). Evolutional and etiological profiles of 40 cases. Ann Dermatol Venereol 2005; 132: 531–4
   Google Scholar
• Borras‐Blasco J., Navarro‐Ruiz A., Devesa P., Montesinos‐Ros A., Gonzalez‐Delgado M. Photo‐induced Stevens‐Johnson syndrome due to sulfasalazine therapy. Ann Pharmacother 2003; 37: 1241–3
   PubMedGoogle Scholar
• Gimnig J. E., MacArthur J. R., M'bang'ombe M., Kramer M. H., Chizani N., Stern R. S., et al. Severe cutaneous reactions to sulfadoxine‐pyrimethamine and trimethoprim‐sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 2006; 74: 738–43
   PubMed Web of Science ®Google Scholar
• La Grenade L., Lee L., Weaver J., Bonnel R., Karwoski C., Governale L., et al. Comparison of reporting of Stevens‐Johnson syndrome and toxic epidermal necrolysis in association with selective COX‐2 inhibitors. Drug Saf 2005; 28: 917–24
   PubMed Web of Science ®Google Scholar
• Goldberg D., Panigrahi D., Barazi M., Abelson M., Butrus S. A case of rofecoxib‐associated stevens‐johnson syndrome with corneal and conjunctival changes. Cornea 2004; 23: 736–7
   PubMedGoogle Scholar
• Sarris B. M., Wong J. G. Multisystem hypersensitivity reaction to lamotrigine. Neurology 1999; 53: 1367
   PubMed Web of Science ®Google Scholar
• Chia F. L., Leong K. P. Severe cutaneous adverse reactions to drugs. Curr Opin Allergy Clin Immunol 2007; 7: 304–9
   Web of Science ®Google Scholar
• Mockenhaupt M., Messenheimer J., Tennis P., Schlingmann J. Risk of Stevens‐Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134–8
   PubMed Web of Science ®Google Scholar
• Chen K. T., Twu S. J., Chang H. J., Lin R. S. Outbreak of Stevens‐Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Public Health 2003; 93: 489–92
   Google Scholar
• Narayan V. S., Mamatha G. P., Ashok L., Rajashekar N. Stevens Johnson syndrome due to I.V Ceftriaxone—a case report. Indian J Dent Res 2003; 14: 220–3
   Google Scholar
• Liberopoulos E. N., Liamis G. L., Elisaf M. S. Possible cefotaxime‐induced Stevens‐Johnson syndrome. Ann Pharmacother 2003; 37: 812–4
   PubMed Web of Science ®Google Scholar
• Cac N. N., Messingham M. J., Sniezek P. J., Walling H. W. Stevens‐Johnson syndrome induced by doxycycline. Cutis 2007; 79: 119–22
   Google Scholar
• Chang Y. S., Huang F. C., Tseng S. H., Hsu C. K., Ho C. L., Sheu H. M. Erythema multiforme, Stevens‐Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007; 26: 123–9
   Web of Science ®Google Scholar
• Marazzi M. C., Germano P., Liotta G., Guidotti G., Loureiro S., da Gruz Gomes A., et al. Safety of nevirapine–containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV‐1 infected pregnant women. HIV Med 2006; 7: 338–44
   PubMed Web of Science ®Google Scholar
• Colebunders R., Vanwolleghem T., Meurrens P., Moerman F. Efavirenz‐associated Stevens‐Johnson syndrome. Infection 2004; 32: 306–7
   Google Scholar
• Terrab Z., El Ouazzani T., Zouhair K., El Kabli H., Lakhdar H. Terbinafine‐induced Stevens‐Johnson syndrome and aggravation of systemic lupus erythematosus. Ann Dermatol Venereol 2006; 133: 463–6
   PubMedGoogle Scholar
• Davis M. D., Rogers R. S 3rd. Pittelkow MR. Recurrent erythema multiforme/Stevens‐Johnson syndrome: response to mycophenolate mofetil. Arch Dermatol 2002; 138: 1547–50
   PubMedGoogle Scholar